



Recent Research on Mesothelioma

Guest Editors:

Dr. Jari Räsänen

1. Department of Cardiothoracic Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 2. Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Dr. Ilkka Ilonen

1. Department of General and Oesophageal Surgery, Lung and Heart Centre, Helsinki University Hospital, Helsinki, Finland. 2. Department of Surgery, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Deadline for manuscript submissions:

closed (20 January 2024)

Message from the Guest Editors

Dear Colleagues,

This Special Issue is about malignant mesothelioma, an aggressive cancer type with grim prognosis. Work-related asbestos exposure is the main cause of this disease. Despite the decrease in the use of asbestos and its known potent carcinogenicity, there are no clear signs of attenuation in centers that treat this disease. The global estimation of the annual deaths related to mesothelioma is 38,400 individuals, making this a global health issue.

With the advent of personalized cancer medicine, there have been recent promising results obtained by maximizing tri-modality therapy (chemotherapy, radiation therapy, and surgery), CAR T-cell therapy, and immune checkpoint inhibitors to name few. We have also gained new insight into the pathogenesis of this disease.

We invite researchers to submit manuscripts for this Special Issue in every aspect of mesothelioma research (basic science, translational, and clinical), as well as the impact and causes of mesothelioma, as the nature of this disease has changed from heavy industrial asbestos exposure to more latent exposure.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)